Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)

The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested for its therapeutic effect on NASH; however, no...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Ryo Goto, Kenya Kamimura, Yoko Shinagawa‐Kobayashi, Norihiro Sakai, Takuro Nagoya, Yusuke Niwa, Masayoshi Ko, Kohei Ogawa, Ryosuke Inoue, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Satoshi Abe, Hiroshi Nishina, Shuji Terai
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2019-04-01
Serie:	FEBS Open Bio
Soggetti:	d‐rR/Tokyo medaka liver fibrosis NASH SGLT2 tofogliflozin
Accesso online:	https://doi.org/10.1002/2211-5463.12598
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!